Knee arthroscopy is the most common orthopedic procedure worldwide. While incidence of post-arthroscopy venous thromboembolic events (VTE) is low, treatment patterns and patient outcomes have not been described. Patients from the “Registro Informatizado Enfermedad TromboEmbolica” who had confirmed post-arthroscopy VTE were compared to patients with provoked, post bone-fracture, and to patients with unprovoked VTE. Baseline characteristics, presenting signs and symptoms, treatment and outcomes including recurrent VTE, bleeds or death were compared. A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE were identified. Post-arthroscopy patients were younger (49.5 vs. 66 years, P < 0.0001) and had less history of VTE [5.9% vs. 20%, OR 0.26 (0.11–0.59)]. Among patients with isolated DVT, there were fewer proximal DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06–0.19)]. Treatment duration was shorter in the post-arthroscopy group (174 ± 140 vs. 311 ± 340 days, P < 0.0001) and more often with DOAC [OR 3.67 (1.95–6.89)]. Recurrent VTE occurred in 6.18 (1.96–14.9) and 11.9 (11.0–12.8) per 100 patient years [HR 0.52 (0.16–1.26)] after treatment in the post-arthroscopy and unprovoked groups, respectively. Recurrent VTE occurred in 5.17 (1.31–14.1) per 100 patient years in a separate post bone-fracture group (n = 147), also not statistically different than the post-arthroscopy recurrence rate. After anticoagulation cessation, some patients post-knee arthroscopy develop VTE. While our small sample size precludes drawing firm conclusions, this signal should warrant further research into the optimal treatment duration for these patients, as some patients may be at increased risk for long-term recurrence.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Delis KT, Hunt N, Strachan RK, Nicolaides AN (2001) Incidence, natural history and risk factors of deep vein thrombosis in elective knee arthroscopy. Thromb Haemost 86:817–821
Kim S, Bosque J, Meehan JP, Jamali A, Marder R (2011) Increase in outpatient knee arthroscopy in the United States: a comparison of National Surveys of Ambulatory Surgery, 1996 and 2006. J Bone Joint Surg Am 93:994–1000
van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB, Nelissen R, Cannegieter SC (2017) Pot K and Group P-C. thromboprophylaxis after knee arthroscopy and lower-leg casting. N Engl J Med 376:515–525
Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J, Jiang Q (2014) Incidence of symptomatic and asymptomatic venous thromboembolism after elective knee arthroscopic surgery: a retrospective study with routinely applied venography. Arthroscopy 30:818–822
Graham WC, Flanigan DC (2014) Venous thromboembolism following arthroscopic knee surgery: a current concepts review of incidence, prophylaxis, and preoperative risk assessment. Sports Med 44:331–343
Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J (1998) Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 158:47–50
Jameson SS, Dowen D, James P, Serrano-Pedraza I, Reed MR, Deehan D (2012) Complications following anterior cruciate ligament reconstruction in the English NHS. Knee 19:14–19
Ilahi OA, Reddy J, Ahmad I (2005) Deep venous thrombosis after knee arthroscopy: a meta-analysis. Arthroscopy 21:727–730
Ye S, Dongyang C, Zhihong X, Dongquan S, Jin D, Jianghui Q, Jizhen Q, Pu Y, Huacheng H, Wei S, Qing J (2013) The incidence of deep venous thrombosis after arthroscopically assisted anterior cruciate ligament reconstruction. Arthroscopy 29:742–747
van Adrichem RA, Nelissen RG, Schipper IB, Rosendaal FR, Cannegieter SC (2015) Risk of venous thrombosis after arthroscopy of the knee: results from a large population-based case-control study. J Thromb Haemost 13:1441–1448
Seon JK, Song EK, Yoon TR, Park SJ, Seo HY (2006) An unusual case of pulmonary embolism after arthroscopic meniscectomy. Arch Orthop Trauma Surg 126:641–643
Takigami J, Hashimoto Y, Yamasaki S, Terai S, Nakamura H (2017) A case of asymptomatic bilateral massive pulmonary embolism after arthroscopic multiple knee ligament reconstruction. Knee Surg Sports Traumatol Arthrosc 25:260–262
Poulsen KA, Borris LC, Lassen MR (1993) Thromboembolic complications after arthroscopy of the knee. Arthroscopy 9:570–573
Egermayer P (1999) Mortality of untreated deep vein thrombosis following knee arthroscopy. Chest 115:604
Navarro-Sanz A, Fernandez-Ortega JF (2004) Fatal pulmonary embolism after knee arthroscopy. Am J Sports Med 32:525–528
Rozencwaig R, Shilt JS, Ochsner JL Jr (1996) Fatal pulmonary embolus after knee arthroscopy. Arthroscopy 12:240–241
Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J, Qin J, Jiang Q (2014) Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis. Arthroscopy 30:406–412
Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM, Group KS (2008) Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med 149:73–82
Camporese G, Bernardi E, Noventa F, Bosco M, Monteleone G, Santoro L, Bortoluzzi C, Freguja S, Nardin M, Marullo M, Zanon G, Mazzola C, Damiani G, Maniscalco P, Imberti D, Lodigiani C, Becattini C, Tonello C, Agnelli G, Group ES (2016) Efficacy of rivaroxaban for thromboprophylaxis after knee arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. Thromb Haemost 116:349–355
Cancienne JM, Diduch DR, Werner BC (2017) High altitude is an independent risk factor for postoperative symptomatic venous thromboembolism after knee arthroscopy: a matched case–control study of medicare patients. Arthroscopy 33:422–427
Krych AJ, Sousa PL, Morgan JA, Levy BA, Stuart MJ, Dahm DL (2015) Incidence and risk factor analysis of symptomatic venous thromboembolism after knee arthroscopy. Arthroscopy 31:2112–2118
Mauck KF, Froehling DA, Daniels PR, Dahm DL, Ashrani AA, Crusan DJ, Petterson TM, Bailey KR, Heit JA (2013) Incidence of venous thromboembolism after elective knee arthroscopic surgery: a historical cohort study. J Thromb Haemost 11:1279–1286
Gaskill T, Pullen M, Bryant B, Sicignano N, Evans AM, DeMaio M (2015) The prevalence of symptomatic deep venous thrombosis and pulmonary embolism after anterior cruciate ligament reconstruction. Am J Sports Med 43:2714–2719
Bikdeli B, Jimenez D, Hawkins M, Ortiz S, Prandoni P, Brenner B, Decousus H, Masoudi FA, Trujillo-Santos J, Krumholz HM, Monreal M, Investigators R, Rationale (2018) Design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 118:214–224
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352
Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton III LJ (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160:761–768
Nemeth B, van Adrichem RA, Cannegieter SC (2016) The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy. Thromb Haemost 116:1001
We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG’s support was limited to the part of RIETE outside Spain, which accounts for a 25.02% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support and Prof. Salvador Ortiz, Universidad Autónoma Madrid and Silvia Galindo, both Statistical Advisors in S&H Medical Science Service for the statistical analysis of the data presented in this paper.
Coordinator of the RIETE Registry: Dr. Manuel Monreal (Spain). RIETE Steering Committee Members: Dr. Paolo Prandoni (Italy), Dr. Benjamin Brenner (Israel), Dr. Dominique Farge-Bancel (France). RIETE National Coordinators: Dr. Raquel Barba (Spain), Dr. Pierpaolo Di Micco (Italy), Dr. Laurent Bertoletti (France), Dr. Inna Tzoran (Israel), Dr. Abilio Reis (Portugal), Dr. Henri Bounameaux (Switzerland), Dr. Radovan Malý (Czech Republic), Dr. Peter Verhamme (Belgium), Dr. Marijan Bosevski (Republic of Macedonia), Dr. Joseph A. Caprini (USA), Dr. Hanh My Bui (Vietnam). RIETE Registry Coordinating Center: S & H Medical Science Service. Members of the RIETE Group: Spain: Adarraga MD, Agudo P, Aibar MA, Aibar J, Amado C, Akasbi M, Aranda C, Arcelus JI, Arenas A, Ballaz A, Barba R, Barrón M, Barrón-Andrés B, Bascuñana J, Blanco-Molina A, Camon AM, Carrasco C, Castro J, Cruz AJ, de Ancos C, del Toro J, Demelo P, Díaz-Pedroche MC, Díaz-Peromingo JA, Falgá C, Farfán AI, Fernández-Capitán C, Fidalgo MA, Font C, Font L, García MA, García-Bragado F, García-Morillo M, García-Raso A, Gavín O, Gayol MC, Gil-Díaz A, Gómez V, González-Martínez J, Grau E, Gutiérrez J, Hernández-Blasco L, Iglesias M, Jara-Palomares L, Jaras MJ, Jiménez D, Jou I, Joya MD, Lalueza A, Lima J, Llamas P, Lobo JL, López-Jiménez L, López-Miguel P, López-Nuñez JJ, López-Reyes R, López-Sáez JB, Lorente MA, Lorenzo A, Loring M, Loscos S, Lumbierres M, Marchena PJ, Martín-Fernández M, Martín-Guerra JM, Martín-Romero M, Mellado M, Modesto M, Monreal M, Morales MV, Nieto JA, Núñez A, Núñez MJ, Olivares MC, Otalora S, Otero R, Pedrajas JM, Pellejero G, Pérez-Jacoiste A, Pérez-Rus G, Peris ML, Pesce ML, Porras JA, Rivas A, Rodríguez-Dávila MA, Rodríguez-Fernández L, Rodríguez-Hernández A, Rosa V, Rosillo-Hernández EM, Rubio CM, Ruiz-Alcaraz S, Ruiz-Artacho P, Ruiz-Ruiz J, Ruiz-Sada P, Sahuquillo JC, Sampériz A, Sánchez-Muñoz-Torrero JF, Sancho T, Sanoja ID, Soler S, Soto MJ, Suriñach JM, Tapia E, Torres MI, Trujillo-Santos J, Uresandi F, Usandizaga E, Valle R, Vela JR, Vilar C, Argentina: Gutiérrez P, Vázquez FJ, Vilaseca A, Belgium: Vanassche T, Vandenbriele C, Verhamme P, Brazil: Yoo HHB, Czech Republic: Hirmerova J, Malý R, Ecuador: Salgado E, France: Benzidia I, Bertoletti L, Bura-Riviere A, Debourdeau P, Falvo N, Farge-Bancel D, Hij A, Mahé I, Moustafa F, Israel: Braester A, Brenner B, Ellis M, Tzoran I, Italy: Barillari G, Bilora F, Bortoluzzi C, Brandolin B, Bucherini E, Camerota A, Ciammaichella M, Dentali F, Di Micco P, Grandone E, Imbalzano E, Lessiani G, Maida R, Mastroiacovo D, Ngoc V, Pace F, Parisi R, Pesavento R, Pinelli M, Prandoni P, Quintavalla R, Rocci A, Siniscalchi C, Sotgiu P, Tufano A, Visonà A, LATVIA: Gibietis V, Skride A, Strautmane S, Republic of Macedonia: Bosevski M, Zdraveska M, Switzerland: Bounameaux H, Mazzolai L, USA: Caprini J, Vietnam: Bui HM.
This study was funded by Sanofi Spain with an unrestricted educational grant and Bayer Pharma AG. Bayer Pharma AG’s support was limited to the part of RIETE outside Spain, which accounts for a 25.02% of the total patients included in the RIETE Registry.
Conflict of interest
Ido Weinberg serves on the Scientific Advisory Board, Novate Medical. Jay Giri serves on the Board of Directors for PERT Consortium, a 501c3 not-for-profit organization. Raghu Kolluri serves on the Board of Directors for VIVA Physicians Inc, a 501c3 not-for-profit organization. He is a paid consultant or serves on the Advisory Board for Medtronic, Philips/Volcano, BTG, Janssen, Vesper Medical, Innovein, Spectranetics, Inari, Boston Scientific. He has received research support from BTG. Juan Ignacio Arcelus, Conxita Falgá, Silvia Soler, Andrei Braester, José Bascuñana, Javier Gutiérrez-Guisado and Manuel Monreal declares no conflicts of interests.
Participating centers have local Institutional Review Board approval with patients providing informed consent for registry enrollment.
A full list of the RIETE investigators is given in Acknowledgements section.
About this article
Cite this article
Weinberg, I., Giri, J., Kolluri, R. et al. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry. J Thromb Thrombolysis 46, 551–558 (2018). https://doi.org/10.1007/s11239-018-1736-9
- Venous thromboembolism
- Knee arthroscopy
- Deep vein thrombosis
- Pulmonary embolism